Medivir Transfers HIV Drug Alovudine License To Beijing Mefuvir
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sweden-based Medivir AB will transfer its license and intellectual property for its HIV drug Alovudine (MIV-310) to subsidiary Beijing Mefuvir, Medivir announced Dec. 21
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)